未登录

Z

Zetian Gong

Nanjing Medical University

H指数:9

被引数:382

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Perioperative blood staging based on personalized ctDNA assay for recurrence prediction in NSCLC

基于个性化ctDNA检测的围手术期血液分期用于预测NSCLC复发

npj Precision Oncology

IF8

2026-09-150

OA

USP7-mediated deubiquitination of the KEAP1-NRF2-HMOX1 axis enhances radioresistance in non-small cell lung cancer by suppressing ferroptosis

USP7介导的KEAP1-NRF2-HMOX1轴的去泛素化通过抑制铁死亡增强非小细胞肺癌的放射抵抗性

IF7.3

2026-04-230

OAAI

Machine learning identifies TIME subtypes linking EGFR mutations and immune states in lung adenocarcinoma

机器学习识别出TIME亚型，将EGFR突变与肺癌腺癌中的免疫状态联系起来

npj Digital Medicine

IF15.1

2025-11-260

OAAI

Revealing the role of regulatory T cells in the tumor microenvironment of lung adenocarcinoma: a novel prognostic and immunotherapeutic signature

揭示调节性T细胞在肺腺癌肿瘤微环境中的作用: 一种新的预后和免疫治疗特征

FRONTIERS IN IMMUNOLOGY

IF5.9

2023-08-2114

OAAI

Tumor-informed fixed and patient-specific panels for minimal residual disease (MRD) detection in early-stage NSCLC:a head-to-head comparison

CANCER RESEARCH

IF16.6

2023-04-040

PRE

The integrated single-cell analysis developed a lactate metabolism-driven signature to improve outcomes and immunotherapy in lung adenocarcinoma

FRONTIERS IN ENDOCRINOLOGY

IF4.6

2023-03-2219

OAAI

By integrating single-cell RNA-seq and bulk RNA-seq in sphingolipid metabolism, CACYBP was identified as a potential therapeutic target in lung adenocarcinoma

通过整合鞘脂代谢中的单细胞rna-seq和bulk rna-seq，CACYBP被确定为肺腺癌的潜在治疗靶点

FRONTIERS IN IMMUNOLOGY

IF5.9

2023-01-2735

OAAI

Cuproptosis-related lncRNA signatures: Predicting prognosis and evaluating the tumor immune microenvironment in lung adenocarcinoma

FRONTIERS IN ONCOLOGY

IF3.3

2023-01-1719

OAAI

A pan-cancer analysis revealed the role of the SLC16 family in cancer

IF3.2

2021-08-2324

OAAI